Press releases

Stockholm – April 1, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5

Stockholm – March 11, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that it has received the first order of its flagship drug Pepaxti (melflufen) from an Italian hospital

Stockholm — 28 February, 2025 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s issue of 10,572,577 new class C shares. The shares are issued by virtue of the Annual General Meetings’ resolution on 31 May 2024 on authorisation for the Board of Directors to resolve on issue of class C shares to enable delivery of shares to participants under the incentive programs Co-worker LTIP 2022, Co-worker LTIP 2024 and Board SHP 2024 as well as other outstanding shareholder programs for members of the Board of Directors

Stockholm – February 27, 2025 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on difficult-to-treat cancers, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 31 May 2024, to issue and immediately thereafter re-purchase a total of 10,572,577 class C shares

Stockholm – February 27, 2025 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on difficult-to-treat cancers, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 31 May 2024, to issue and immediately thereafter re-purchase a total of 10,572,577 class C shares

Stockholm – February 27, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2024

Stockholm – February 25, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus dexamethasone in patients with relapsed, refractory multiple myeloma (RRMM) has been published in the peer-reviewed journal European Journal of Haematology

Stockholm – February 20, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the fourth quarter and the 2024 year-end report, at 08:00 CET on February 27, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on February 27 at 09:00 CET

Stockholm, February 5, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that Jarl Ulf Jungnelius has informed the Board of Directors of his decision to step down from the Bord of Directors of Oncopeptides in which he has served since 2011. This due to personal reasons related to a change of domicile from Sweden

Stockholm, January 27, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the Italian Official Journal (“IOJ”, It.: Gazetta Ufficiale). This marks the final regulatory step for the drug’s upcoming commercialization in Italy, confirming Oncopeptides’ expectation of first sales during H1, 2025